RAD.AX - Radiopharm Theranostics Limited

Radiopharm Theranostics Limited

62 Lygon Street
Level 3
Carlton, VIC 3053
Australia
61 3 9824 5254
https://www.radiopharmtheranostics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD	Founder & Exec. Chairman	291.04k	N/A	1956
Mr. Riccardo Canevari	MD, CEO & Director	2.06M	N/A	N/A
Mr. Phillip Hains	CFO & Company Sec.	N/A	N/A	N/A
Prof. David Mozley	Chief Medical Officer & Scientific Advisory Board Chair	860.77k	N/A	N/A
Mr. Vittorio Puppo M.D.	Chief Operating Officer	N/A	N/A	N/A
Dr. Thomas H. Tulip Ph.D.	Chief Technical Officer	N/A	N/A	1953
Dr. Scot L. Harper Ph.D.	Sr. VP of Clinical Operations	N/A	N/A	1957
Mr. Bill Regan	Sr. VP of Regulatory Strategy	N/A	N/A	N/A
Dr. Rama Abu Shmeis	Sr. VP of Chemistry, Manufacturing & Controls	N/A	N/A	N/A
Mr. Nathan Jong C.A.	Company Sec.	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Radiopharm Theranostics Limited develops radiopharmaceutical products for diagnostic and therapeutic uses. The company was incorporated in 2021 and is based in Carlton, Australia.

Corporate governance

Radiopharm Theranostics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.